(0.33%) 5 116.86 points
(0.41%) 38 398 points
(0.47%) 16 002 points
(-1.59%) $82.52
(4.84%) $2.02
(0.19%) $2 351.70
(0.21%) $27.59
(4.16%) $960.45
(-0.22%) $0.933
(-0.38%) $10.98
(-0.54%) $0.796
(1.69%) $93.42
Live Chart Being Loaded With Signals
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally...
Stats | |
---|---|
Šios dienos apimtis | 3.19M |
Vidutinė apimtis | 4.48M |
Rinkos kapitalizacija | 6 415.37B |
EPS | ¥0 ( 2024-02-01 ) |
Kita pelno data | ( ¥1.100 ) 2024-05-08 |
Last Dividend | ¥90.00 ( 2023-03-30 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | 36.36 |
ATR14 | ¥1.540 (0.04%) |
Tūris Koreliacija
Takeda Pharmaceutical Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Takeda Pharmaceutical Koreliacija - Valiuta/Žaliavos
Takeda Pharmaceutical Finansinės ataskaitos
Annual | 2022 |
Pajamos: | ¥4 027.48B |
Bruto pelnas: | ¥2 783.41B (69.11 %) |
EPS: | ¥204.29 |
FY | 2022 |
Pajamos: | ¥4 027.48B |
Bruto pelnas: | ¥2 783.41B (69.11 %) |
EPS: | ¥204.29 |
FY | 2022 |
Pajamos: | ¥3 569.01B |
Bruto pelnas: | ¥2 462.16B (68.99 %) |
EPS: | ¥147.14 |
FY | 2021 |
Pajamos: | ¥3 197.81B |
Bruto pelnas: | ¥2 203.50B (68.91 %) |
EPS: | ¥240.72 |
Financial Reports:
No articles found.
Takeda Pharmaceutical Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥90.00 (N/A) |
¥0 (N/A) |
¥90.00 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥16.50 | 2000-03-28 |
Last Dividend | ¥90.00 | 2023-03-30 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 48 | -- |
Total Paid Out | ¥3 458.50 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.84 | -- |
Div. Sustainability Score | 4.76 | |
Div.Growth Potential Score | 4.33 | |
Div. Directional Score | 4.54 | -- |
Year | Amount | Yield |
---|
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
8365.T | Ex Dividend Junior | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
7745.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
6927.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
6289.T | Ex Dividend Knight | 2023-08-30 | Semi-Annually | 0 | 0.00% | |
5011.T | Ex Dividend Junior | 2023-09-28 | Annually | 0 | 0.00% | |
4212.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
3420.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
2502.T | Ex Dividend Knight | 2023-12-28 | Semi-Annually | 0 | 0.00% | |
9436.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
8089.T | Ex Dividend Junior | 2023-09-28 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0427 | 1.500 | 9.15 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0125 | 1.200 | 9.58 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0263 | 1.500 | -0.819 | -1.228 | [0.1 - 1] |
payoutRatioTTM | 1.619 | -1.000 | 10.00 | -10.00 | [0 - 1] |
currentRatioTTM | 1.064 | 0.800 | 9.68 | 7.74 | [1 - 3] |
quickRatioTTM | 0.465 | 0.800 | -1.972 | -1.578 | [0.8 - 2.5] |
cashRatioTTM | 0.126 | 1.500 | -0.409 | -0.614 | [0.2 - 2] |
debtRatioTTM | 0.328 | -1.500 | 4.53 | -6.80 | [0 - 0.6] |
interestCoverageTTM | 1.450 | 1.000 | -0.574 | -0.574 | [3 - 30] |
operatingCashFlowPerShareTTM | 466.22 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | -82.25 | 2.00 | -10.00 | -10.00 | [0 - 20] |
debtEquityRatioTTM | 0.692 | -1.500 | 7.23 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.675 | 1.000 | 2.08 | 2.08 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0750 | 1.000 | -0.500 | -0.500 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.157 | 1.000 | -0.240 | -0.240 | [0.2 - 2] |
assetTurnoverTTM | 0.293 | 0.800 | -1.379 | -1.103 | [0.5 - 2] |
Total Score | 4.76 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 36.00 | 1.000 | 6.47 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0263 | 2.50 | -0.526 | -1.228 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -82.25 | 2.00 | -10.00 | -10.00 | [0 - 30] |
dividendYielPercentageTTM | 4.60 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 466.22 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 1.619 | 1.500 | 10.00 | -10.00 | [0 - 1] |
pegRatioTTM | 0.927 | 1.500 | 7.15 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.175 | 1.000 | 8.11 | 0 | [0.1 - 0.5] |
Total Score | 4.33 |
Takeda Pharmaceutical
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.